(Gastric Cancer) Nivolumab Can Extend Overall Survival
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- November 16, 2016
- Read time: 1 minute
Ono Pharmaceutical announced on November 10 the results from the ONO-4538-12 analysis, showing that anti-PD-1 antibody nivolumab (Opdivo) can extend overall survival in unresectable advanced or recurrent gastric cancer patients who do not meet the criteria for standard treatment. The full trial results will be publicly presented at the Gastrointestinal Cancers Symposium (ASCO GI) in 2017. Please look forward to ASCO 2017!
Regarding drug information for gastric cancer, pembrolizumab (Keytruda) is currently under accelerated review. The application timeline for nivolumab (Opdivo) is not yet known, but there are high expectations for the effects of these two anti-PD-1 antibodies being used simultaneously.
For those interested, you may refer to this page from Bristol-Myers Squibb, which contains information about this clinical trial and the methods they are implementing.
About ONO-4538-12:
ONO-4538-12 is a multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical trial conducted in Japan, Korea, and Taiwan, aiming to evaluate the efficacy and safety of Opdivo in patients with unresectable advanced or recurrent gastric cancer, including gastroesophageal junction cancer, refractory to or intolerant of standard therapy. In this study, Opdivo 3 mg/kg or placebo was administered every two weeks until disease progression or discontinuation due to unacceptable toxicity. The primary endpoint, overall survival, was assessed for the superiority of Opdivo versus placebo.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4